| Literature DB >> 24023737 |
Odu Okoturo-Evans1, Agnieszka Dybowska, Eugenia Valsami-Jones, John Cupitt, Magdalena Gierula, Alan R Boobis, Robert J Edwards.
Abstract
A study into the effects of amorphous nano-SiO2 particles on A549 lung epithelial cells was undertaken using proteomics to understand the interactions that occur and the biological consequences of exposure of lung to nanoparticles. Suitable conditions for treatment, where A549 cells remained viable for the exposure period, were established by following changes in cell morphology, flow cytometry, and MTT reduction. Label-free proteomics was used to estimate the relative level of proteins from their component tryptic peptides detected by mass spectrometry. It was found that A549 cells tolerated treatment with 100 µg/ml nano-SiO2 in the presence of 1.25% serum for at least 4 h. After this time detrimental changes in cell morphology, flow cytometry, and MTT reduction were evident. Proteomics performed after 4 h indicated changes in the expression of 47 proteins. Most of the proteins affected fell into four functional groups, indicating that the most prominent cellular changes were those that affected apoptosis regulation (e.g. UCP2 and calpain-12), structural reorganisation and regulation of actin cytoskeleton (e.g. PHACTR1), the unfolded protein response (e.g. HSP 90), and proteins involved in protein synthesis (e.g. ribosomal proteins). Treatment with just 10 µg/ml nano-SiO2 particles in serum-free medium resulted in a rapid deterioration of the cells and in medium containing 10% serum the cells were resistant to up to 1000 µg/ml nano-SiO2 particles, suggesting interaction of serum components with the nanoparticles. A variety of serum proteins were found which bound to nano-SiO2 particles, the most prominent of which were albumin, apolipoprotein A-I, hemoglobin, vitronectin and fibronectin. The use of a proteomics platform, with appropriately designed experimental conditions, enabled the early biological perturbations induced by nano-SiO2 in a model target cell system to be identified. The approach facilitates the design of more focused test systems for use in tiered evaluations of nanomaterials.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24023737 PMCID: PMC3762866 DOI: 10.1371/journal.pone.0072363
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Physico-chemical characteristics of the nano-SiO2 preparation.
(A) XRD analysis confirming the sample is amorphous silica. (B) FTIR spectrum indicating the presence of non-functionalised surfaces in the sample. (C) TEM image showing monodispersed particles with an average size of 25±2 nm. (D) DLS intensity weighed particle size distributions of nano-SiO2 particles in water, cell culture medium containing 1.25% serum (in the absence of nano-SiO2 particles), nano-SiO2 particles in cell culture medium containing 1.25% serum immediately after dispersion (0 h) and then after incubation at 37°C for 4 h and 24 h. (E) Changes in the average particle size (estimated from DLS) of nano-SiO2 dispersed in culture medium containing 1.25% serum at 37°C for up to 24 h.
Morphological changes in A549 cells resulting from incubation with nano-SiO2.
| Nano-SiO2 (µg/ml) | |||||
| time (h) | 0 | 1 | 10 | 100 | 1000 |
|
| |||||
| 0 | + | + | + | + | + |
| 1 | + | + | + | + | + |
| 2 | + | + | + | + | + |
| 4 | + | + | + | + | + |
| 6 | + | + | + | + | + |
| 8 | + | + | + | + | + |
| 24 | + | + | + | + | + |
|
| |||||
| 0 | + | + | + | + | + |
| 1 | + | + | + | + | − |
| 2 | + | + | + | + | − |
| 4 | + | + | + | + | − |
| 6 | + | + | + | − | − |
| 8 | + | + | + | − | − |
| 24 | + | + | + | − | − |
|
| |||||
| 0 | + | + | + | + | + |
| 1 | + | + | + | − | − |
| 2 | + | + | − | − | − |
| 4 | + | + | − | − | − |
| 6 | + | + | − | − | − |
| 8 | + | + | − | − | − |
| 24 | + | + | − | − | − |
A series of experiments were performed in which A549 cells were incubated with a variety of concentrations of nano-SiO2 for up to 24 h in medium containing different quantities of serum. The condition of the cells following treatment for different periods of time was assessed by light microscopy. In the absence of nano-SiO2 the cells grew normally with characteristic squamous cell morphology in the form of an adherent monolayer with very few rounded or floating cells (see figure 2). Those cultures that maintained such an appearance are indicated as ‘+’. In those cultures that responded to treatment with nano-SiO2 resulting in any cell abnormalities are indicated as ‘−’ (figure 2). Each set of conditions was replicated 3-times in separate cultures.
Figure 2Typical morphology and flow cytometry of A549 cells.
(A) Cells with a normal morphology as observed by light microscopy (magnification X250). Flow cytometry showed a relatively discrete distribution of fluorescent signals within the indicated area of interest. (B) Following treatment at effective doses a fraction of the cells took on a rounded appearance and became detached from the surface. Flow cytometry indicated a spread in the distribution of fluorescent signals outside the region of interest. (C). Later the cells became largely detached from the surface, started to clump together and lose their integrity; under such conditions very few cells were detected by flow cytometry.
Figure 3Flow cytometric analysis of A549 cells following treatment with nano-SiO2.
A549 cells were treated for up to 24% serum (filled circles), 100 µg/ml nano-SiO2 in medium containing 1.25% serum (solid squares), and 10 µg/ml nano-SiO2 in serum-free medium (solid diamonds). At each time point the relative number of cells with fluorescent measurements in the region of interest (ROI) (see figure 2) are shown.
Figure 4Assessment of the condition of A549 cells by MTT reduction.
A549 cells were treated with up to 100 µg/ml nano-SiO2 for up to 24 h in the presence of (A) serum-free medium or (B) medium containing 1.25% serum. At each time point the ability of the cells to reduce MTT was determined. Each determination was performed in triplicate. The data have been plotted as surface plots that show the combined effect of treatment dose and time on MTT reduction. The colours represent different relative absorbance thresholds of MTT reduction as indicated by the scale.
Figure 5SDS-PAGE gel showing the distribution of proteins in A549 whole cell lysates.
Replicate cell cultures grown in medium containing 1.25% serum were treated with vehicle control and 100 µg/ml nano-SiO2 A549 whole cell lysates for 4 h (n = 5). The gel was cut into 12 horizontal slices based on the migration of PageRuler Prestained Protein Ladder markers as a guide; each slice was further divided between each of the protein lanes to give 10 gel pieces for each row giving a total of 120 samples for analysis in this experiment.
Figure 6Volcano plot analysis showing the effect of nano-SiO2 treatment on protein expression in A549 cells.
For each protein detected the relative level of protein expression following treatment is depicted on the basis of both fold change and statistical difference. The main proteins of interest are those furthest from the origin, and these are indicated as open triangles.
Differentially expressed proteins in A549 cells following treatment with nano-SiO2 particles.
| Proteins | NCBI code | Gelregion | Folddifference | Probability |
| Peptide [charge] | X Corr | |||
|
| ||||
| Anoctamin-9 | NP_001012302.2 | 6,7 | 1.8 | 0.045228 |
| LDAIKMVWLQR [2+] | 2.02 | |||
| FFTLQFFTHFSSLIYIAFILGRINGHPGKSTR [3+] | 2.76 | |||
| Bestrophin-4 | NP_695006.1 | 11 | 6.6 | 0.001001 |
| FGGFSGLLLR [2+] | 2.05 | |||
| YANLASVLVLR [2+] | 2.19 | |||
| Calpain-12 | NP_653292.2 | 1 | 6.1 | 0.008969 |
| CCLRPGHYLVVPSTAHAGDEADFTLR [3+] | 2.62 | |||
| TDVCQGSLGNCWFLAAAASLTLYPRLLR [3+] | 2.55 | |||
| Cyclin-dependent kinase 4 inhibitor C | NP_523240.1, NP_001253.1 | 11 | 1.5 | 0.014932 |
| NEVVSLMQANGAGGATNLQ [2+] | 2.57 | |||
| TALQVMKLGNPEIAR [2+] | 2.41 | |||
| Inositol 1,4,5-trisphosphate receptor type 3 | NP_002215.2 | 9,10 | −2.1 | 0.02743 |
| EPVDPTTKGRVASFSIPGSSSR [3+] | 2.6 | |||
| QRLGFVDVQNCISR [2+] | 2.65 | |||
| Mitochondrial uncoupling protein 2 | NP_003346.2 | 11 | 8.0 | 0.000005 |
| AGGGRR [1+] | 1.58 | |||
| FQAQARAGGGR [2+] | 2.18 | |||
| Phosphatase and actin regulator 1 | NP_112210.1, NP_001229577.1 | 7 | −1.9 | 0.004217 |
| SKSDTPYLAEAR [2+] | 2.46 | |||
| RADKPWTR [2+] | 2.17 | |||
| Serine/threonine-protein kinase SMG1 | NP_055907.3 | 10,11 | −1.6 | 0.011783 |
| NLVLKESQR [2+] | 2.13 | |||
| NSASPKHSLNGESR [2+] | 2.01 | |||
| Zygote arrest protein 1 | NP_783318.1 | 11,12 | −25.8 | 0.000204 |
| IDAAVQCSLGRR [2+] | 2.1 | |||
| TVAVYSPLALRR [2+] | 2.26 | |||
|
| ||||
| ATP-binding cassette sub-family A member 5 | NP_061142.2, NP_758424.1 | 1,2 | −1.6 | 0.004972 |
| KKGENVEALR [2+] | 2.19 | |||
| GIGYR [1+] | 1.55 | |||
| ATP-binding cassette sub-family A member 8 | NP_009099.1 | 6,7 | 1.3 | 0.042196 |
| KGCFSKRKNKIATR [2+] | 2.61 | |||
| KNKIATR [1+] | 1.52 | |||
| Brefeldin A-inhibited guanine nucleotide-exchange protein 3 | NP_065073.3 | 5,6 | 1.2 | 0.030546 |
| EWLGRVGR [1+] | 1.52 | |||
| SLSTAPVVQPLSIQDLVR [2+] | 2 | |||
| BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 1 | NP_849194.1 | 8 | 2.1 | 0.01655 |
| AGGAGR [1+] | 1.57 | |||
| GPDPALLEATGGAAGAGGAGR [2+] | 2.23 | |||
| Carboxypeptidase D isoform 1 precursor | NP_001295.2 | 7,8 | 1.7 | 0.043196 |
| EVVGR [1+] | 1.57 | |||
| EAAAAGLPGLAR [2+] | 2.08 | |||
| Conserved oligomeric Golgi complex subunit 8 | NP_115758.3 | 6,7 | −1.2 | 0.008452 |
| MNSLTLNR [1+] | 2.05 | |||
| FPEAQWR [2+] | 2.18 | |||
| E3 ubiquitin-protein ligase UBR5 | NP_056986.2 | 11 | 4.4 | 0.003424 |
| EEASLR [1+] | 1.53 | |||
| MTAREEASLR [2+] | 2.52 | |||
| F-box only protein 41 | NP_001073879.2 | 10,11 | −1.4 | 0.009824 |
| LERLSEEVEQKIAGQVGR [2+] | 2.37 | |||
| ALEKLEVDR [2+] | 2.1 | |||
| Heat shock protein HSP 90-alpha isoform 1 | NP_001017963.2, NP_031381.2, NP_005339.3 | 5,6 | −1.3 | 0.034606 |
| GTKVILHLKEDQTEYLEER [2+] | 2.09 | |||
| GVVDSEDLPLNISR [2+] | 4.22 | |||
| Ras-related protein Rab-5C isoform a | NP_958842.1, NP_001238968.1, NP_004574.2 | 11 | −1.3 | 0.009775 |
| GAQAAIVVYDITNTDTFAR [2+] | 4.66 | |||
| GVDLQENNPASR [2+] | 4.55 | |||
| Rho guanine nucleotide exchange factor 1 isoform 2 | NP_004697.2, NP_945328.1, NP_945353.1 | 11,12 | 2.0 | 0.025357 |
| LLLKSHSR [2+] | 2.18 | |||
| KGGVGMPSR [2+] | 2.02 | |||
| Ubiquitin-like modifier-activating enzyme 1 | NP_003325.2, NP_695012.1 | 2,3 | −2.3 | 0.032011 |
| QMNPHIR [2+] | 2.14 | |||
| LAGTQPLEVLEAVQR [2+] | 3.72 | |||
|
| ||||
| 40S ribosomal protein S9 | NP_001004.2 | 12 | −4.0 | 0.0028 |
| KTYVTPR [2+] | 2.34 | |||
| LFEGNALLR [2+] | 3.81 | |||
| 40S ribosomal protein S13 | NP_001008.1 | 12 | −1.5 | 0.011217 |
| LILIESR [2+] | 2.18 | |||
| DSHGVAQVR [2+] | 2.78 | |||
| 60S ribosomal protein L8 | NP_000964.1, NP_150644.1 | 9 | −5.1 | 0.044527 |
| AVVGVVAGGGR [2+] | 4.1 | |||
| AVDFAER [2+] | 2.53 | |||
| 60S ribosomal protein L13 isoform 1 | NP_150254.1, NP_000968.2, NP_001230059.1, NP_001230060.1 | 11 | −2.8 | 0.00003 |
| VATWFNQPAR [2+] | 3.5 | |||
| TIGISVDPR [2+] | 2.41 | |||
| GFSLEELR [2+] | 2.85 | |||
| Protein PRRC2A | NP_542417.2, NP_004629.3 | 10,11 | −2.0 | 0.000385 |
| GVPSR [1+] | 1.5 | |||
| QGSVTAPGGHPR [2+] | 2.13 | |||
| VNSGLSSDPHFEEPGPMVR [2+] | 2.52 | |||
| Protein SCAF8 | NP_055707.3 | 7 | 2.0 | 0.000273 |
| FPPIETR [2+] | 2.27 | |||
| DVVGRPIDPR [2+] | 2.11 | |||
|
| ||||
| Cadherin EGF LAG seven-pass G-type receptor 3 precursor | NP_001398.2 | 9,10 | 1.6 | 0.047065 |
| GLGGR [1+] | 1.6 | |||
| TQDQDSQR [2+] | 2.02 | |||
| CLIP-associating protein 1 isoform 2 | NP_001135745.1, NP_001135746.1, NP_001193980.1, NP_056097.1 | 11 | −2.0 | 0.009613 |
| KGALLELLKITR [2+] | 2.48 | |||
| ASTVSTKSVSTTGSLQRSR [2+] | 2.52 | |||
| Contactin-5 isoform 1 precursor | NP_001230199.1, NP_001230200.1, NP_780775.1, NP_055176.1 | 7,8 | 2.3 | 0.04553 |
| NGTEIDLESDYR [2+] | 2.85 | |||
| MIRTNEAVPKTAPTNVSGR [3+] | 2.88 | |||
| Diacylglycerol kinase theta | NP_001338.2 | 2,3 | −1.9 | 0.041917 |
| DARADAAPAPESDPR [2+] | 2 | |||
| EGNLPSGAR [1+] | 1.69 | |||
| FYVAESR [1+] | 1.58 | |||
| Elongation factor 1-gamma | NP_001395.1 | 7 | −1.3 | 0.031715 |
| TFLVGER [2+] | 2.69 | |||
| KLDPGSEETQTLVR [2+] | 4.37 | |||
| Homeobox protein unc-4 homolog | NP_001073930.1 | 8 | 2.0 | 0.020386 |
| LDLVESR [1+] | 1.89 | |||
| EALALR [1+] | 1.55 | |||
| Laminin subunit beta-3 precursor | NP_000219.2, NP_001017402.1, NP_001121113.1 | 5 | 1.2 | 0.020519 |
| MEELRHQAR [1+] | 1.84 | |||
| SFNGLLTMYQR [2+] | 2 | |||
| Latent-transforming growth factor beta-binding protein 3 isoform 1 precursor | NP_001123616.1, NP_066548.2 | 9,10 | −1.6 | 0.00904 |
| MNGGQCSSR [2+] | 2.07 | |||
| GLGGR [1+] | 1.6 | |||
| Stomatin-like protein 2 | NP_038470.1 | 7 | −1.2 | 0.030743 |
| ILEPGLNILIPVLDR [2+] | 4.16 | |||
| ATVLESEGTR [2+] | 2.82 | |||
| RAPR [1+] | 1.71 | |||
| TBC1 domain family member 12 | NP_056003.1 | 10,11 | 4.8 | 0.000067 |
| DCRDLEEAR [2+] | 2.11 | |||
| DLEEAR [1+] | 2.26 | |||
| Tetraspanin-32 | NP_620591.3 | 1,2 | −1.4 | 0.029738 |
| QELAAIQDVFLCCGKKSPFSR [3+] | 2.54 | |||
| EDCLQGIR [1+] | 1.89 | |||
| TRAF3-interacting protein 1 isoform 1 | NP_056465.2, NP_001132962.1 | 9,10 | −1.8 | 0.031608 |
| RPPLTEKLLSKPPFR [2+] | 2.25 | |||
| KPREKDKDKEKAKENGGNR [2+] | 2.18 | |||
| Tropomyosin alpha/beta | NP_689476.2, NP_001036816.1, NP_001036817.1, NP_001036818.1, NP_003281.1, NP_705935.1, NP_001138632.1, NP_003280.2, NP_998839.1, NP_001018004.1, NP_001018005.1, NP_001018007.1, NP_001018008.1 | 9 | −1.3 | 0.036743 |
| EQAEAEVASLNR [2+] | 4.06 | |||
| KYEEVAR [2+] | 2.93 | |||
| RIQLVEEELDR [2+] | 3.56 | |||
| IQLVEEELDR [2+] | 3.9 | |||
| AEFAER [1+] | 1.9 | |||
| KLVIIEGDLER [2+] | 2.95 | |||
| Tubulin polyglutamylase TTLL4 | NP_055455.3 | 8,9 | −1.4 | 0.024614 |
| QKWIVKPPASAR [2+] | 2.16 | |||
| IYLFSDGLVR [2+] | 2.11 | |||
| Unconventional myosin-Va isoform 1 | NP_000250.3, NP_001135967.1 | 12 | 4.5 | 0.000106 |
| ACGVLETIR [2+] | 2.26 | |||
| LLESQLQSQKR [2+] | 2.27 | |||
|
| ||||
| Breast carcinoma-amplified sequence 4 isoform b | NP_942094.2, NP_001010974.1, NP_060313.3 | 1,2 | 1.7 | 0.019224 |
| GGGAPR [1+] | 1.63 | |||
| MQRTGGGAPRPGR [2+] | 2.46 | |||
| Cytosolic acyl coenzyme A thioester hydrolase isoform hBACHb | NP_863654.1 | 5,6 | 1.5 | 0.001268 |
| FEEGKGR [1+] | 1.81 | |||
| LVAGQGCVGPRR [2+] | 2.12 | |||
| Histone H4 | NP_001029249.1, NP_003529.1, NP_003530.1, NP_003531.1, NP_003532.1, NP_003533.1, NP_003534.1, NP_003535.1, NP_003536.1, NP_003537.1, NP_003486.1, NP_003539.1, NP_778224.1, NP_068803.1 | 12 | 1.8 | 0.045714 |
| DNIQGITKPAIR [2+] | 3.48 | |||
| ISGLIYEETR [2+] | 4.27 | |||
| TLYGFGG [1+] | 2.39 | |||
| Neogenin isoform 3 precursor | NP_001166095.1, NP_001166094.1, NP_002490.2 | 4,5 | 1.5 | 0.043386 |
| QPLLLDDR [2+] | 2.09 | |||
| SPLVR [1+] | 1.7 | |||
| Uncharacterized protein C13orf30 | NP_872314.1 | 5 | 2.0 | 0.000271 |
| EALSYALVLRDSTKR [3+] | 2.52 | |||
| EALSYALVLR [2+] | 2.24 | |||
| Uncharacterized protein KIAA2013 precursor | NP_612355.1 | 1 | 1.3 | 0.015185 |
| MWLQQRLKGLPGLLSSSWAR [3+] | 2.59 | |||
| GEVVPLGPGVPALVANGFLALDVAANR [3+] | 2.55 |
Cultures of A549 cells (n = 5) were treated for 4 h with 100 µg/ml or vehicle only (n = 5) in medium containing 1.25% serum. Total cell homogenates were prepared, separated by SDS-PAGE, proteins extracted, digested with trypsin and analysed by LC-MS/MS. Relative amounts of each protein were determined from the ion intensity of the component peptides using Progenesis software and those that varied significantly are indicated by probability and fold difference (treated/untreated, except those shown as minus values which represent fold decreases, i.e. untreated/treated). The identity of the component peptides are shown along with their charge and XCorr score.
Figure 7Immunoreactive levels of UCP2.
Immunoblotting was performed on A549 cell homogenates following treatment with vehicle or nano-SiO2 and developed with antibodies against (A) UCP2 or (B) actin. The relative intensity of the immunoreactive bands was determined by densitometry as described in the Materials and Methods.
Figure 8Analysis of proteins that bind to nano-SiO2 particles.
Nano-SiO2 particles were incubated with 1.25% serum only or 1.25% serum and A549 cells. The nanoparticles were recovered and washed by centrifugation and then bound proteins separated by SDS-PAGE which were stained with InstantBlue. For proteomic analysis the gel was cut into 11 horizontal slices based on the migration of proteins markers and the bands in the material eluted from the nanoparticles. Each slice was further divided between each of the protein lanes for analysis by proteomics as detailed in the Materials and Methods.
Serum proteins that bind to nano-SiO2 particles.
| row | protein coverage (%) | |||||||||||
| Protein | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | |
| albumin [Bos taurus] | • | • |
| • | • | • | • | • | • | • | • | 44 |
| alpha-1-antiproteinase [Bos taurus] | • | 21 | ||||||||||
| alpha-2-HS-glycoprotein [Bos taurus] | • | 32 | ||||||||||
| alpha-2-macroglobulin [Bos taurus] | • | 10 | ||||||||||
| annexin A2 [Bos taurus] | • | 29 | ||||||||||
| apolipoprotein A-I [Bos taurus] | • | • | • |
| • | • | • | • | 67 | |||
| apolipoprotein A-II [Bos taurus] | • | 40 | ||||||||||
| apolipoprotein B-100 [Bos taurus] | • | 10 | ||||||||||
| complement C3 [Bos taurus] | • |
| • | • | 16 | |||||||
| complement factor B [Bos taurus] | • | 17 | ||||||||||
| fibronectin [Bos taurus] | • | 12 | ||||||||||
| gelsolin isoform b [Bos taurus] | • | 21 | ||||||||||
| hemoglobin subunit alpha [Bos taurus] | • | 26 | ||||||||||
| hemoglobin, gamma 2 [Bos taurus] | • |
| 56 | |||||||||
| inter-alpha-trypsin inhibitor heavy chain H2 [Bos taurus] |
| • | 12 | |||||||||
| peroxiredoxin-1 [Bos taurus] | • | 18 | ||||||||||
| pigment epithelium- derived factor [Bos taurus] |
| • | 45 | |||||||||
| vitronectin [Bos taurus] | • | 19 | ||||||||||
| Approx. MW (kDa) | 200 | 130 | 75 | 65 | 48 | 32 | 25 | 20 | 16 | 14 | 5 | |
Nano-SiO2 particles were incubated with fetal bovine serum under the same conditions as those used to treat A549 cells. The nanoparticles were recovered and bound proteins identified by proteomics as described in Materials and Methods. The table lists the main proteins identified in each row (the 4 with the highest Sf scores; minimum score of 3.0) and the rows in which they were present. Underlined symbols indicate the row where the highest protein coverage was found. The MW equivalent to the centre of each row is indicated. The experiment was performed twice and also repeated in the presence of A549 cells. A similar result was found on each occasion, i.e. all proteins identified were bovine in origin and none could be attributed to a human source (i.e. A549 cells). MS details supporting the identification of the proteins are provided in Table S2.